Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome

Annals of Surgical Oncology

Volumn 11, Issue 11, 2004, Pages 955-961

  Moore, Harvey G ^a   Shia, Jinru ^a   Klimstra, David S ^a   Ruo, Leyo ^a   Mazumdar, Madhu ^a   Schwartz, Gary K ^a   Minsky, Bruce D ^a   Saltz, Leonard ^a   Guillem, Jose G ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Chemoradiation; Cyclin dependent kinase inhibitor; p27; Rectal neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; ANTINEOPLASTIC ANTIMETABOLITE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERINEUM; PREDICTION; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; ADJUVANT THERAPY; BIOSYNTHESIS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RECTUM TUMOR; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROGNOSIS; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 16644400993     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2004.03.095     Document Type: Article

References (48)

1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-46.
3. Sgambato A, Migaldi M, Faraglia B, et al. Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59:3245-50.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Buglioni S, D'Agnano I, Cosimelli M, et al. Evaluation of multiple bio-pathological factors in colorectal adenocarcinomas: independent prognostic role of p53 and bcl-2. Int J Cancer 1999;84:545-52.
6. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
7. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-8.
8. Arber N, Hibshoosh H, Moss SF, et al. Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996;110:669-74.
9. Maeda K, Chung YS, Kang SM, et al. Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 1997;74:310-5.
10. Maeda K, Chung Y, Kang S, et al. Cyclin D1 overexpression and prognosis in colorectal adenocarcinoma. Oncology 1998;55:145-51.
11. Petrowsky H, Sturm I, Graubitz O, et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001;27:80-7.
12. Kanavaros P, Stefanaki K, Valassiadou K, et al. Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas. Med Oncol 1999;16:23-30.
13. Poller DN, Baxter KJ, Shepherd NA. p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer? Br J Cancer 1997;75:87-93.
14. Backus HH, van Riel JM, van Groeningen CJ, et al. Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 2001;12:779-85.
15. Fredersdorf S, Burns J, Milne AM, et al. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94:6380-5.
16. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
17. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998;58:1730-5.
18. Hirabayashi H, Ohta M, Tanaka H, et al. Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: analysis in combination with expressions of p16INK4A, pRB, and p53. J Surg Oncol 2002;81:177-84; discussion 84.
19. Fiorentino M, Altimari A, D'Errico A, et al. Low p27 expression is an independent predictor of survival for patients with either hilar or peripheral intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7:3994-9.
20. Mori M, Mimori K, Shiraishi T, et al. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
21. Nitti D, Belluco C, Mammano E, et al. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 2002;81:167-75; discussion 75-6.
22. Cheah PY, Choo PH, Yao J, Eu KW, Seow-Choen F. A survival-stratification model of human colorectal carcinomas with beta-catenin and p27kip1. Cancer 2002;95:2479-86.
23. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
24. Palmqvist R, Stenling R, Oberg A, Landberg G. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization. J Pathol 1999;188:18-23.
25. Tenjo T, Toyoda M, Okuda J, et al. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000;58:45-51.
26. Cheng JD, Werness BA, Babb JS, Meropol NJ. Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma. Clin Cancer Res 1999;5:1057-62.
27. Hoos A, Nissan A, Stojadinovic A, et al. Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 2002;8:3841-9.
28. Esposito G, Pucciarelli S, Alaggio R, et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-8.
29. Grann A, Minsky BD, Cohen AM, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum 1997;40:515-22.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
32. Cox D, Oakes D. Analysis of Survival Data. New York: Chapman & Hall, 1990.
33. Sogawa N, Takiguchi N, Koda K, et al. Value of expression of p21WAF1/CIP1 as a prognostic factor in advanced middle and lower rectal cancer patients treated with preoperative radio-chemotherapy. Int J Oncol 2002;21:787-93.
34. Rau B, Sturm I, Lage H, et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 2003;21:3391-401.
35. Yao J, Eu KW, Seow-Choen F, Cheah PY. Down-regulation of p27 is a significant predictor of poor overall survival and may facilitate metastasis in colorectal carcinomas. Int J Cancer 2000;89:213-6.
36. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol 1998;153:681-7.
37. Savarese DM, Wuu J, Yu M, Hsieh C, Banner B. Immunostaining for p53 and p27 in primary and metastatic colorectal tumors as predictors of outcome and response to chemotherapy (abstract). Proc Am Soc Clin Oncol 1998;17:A1038.
38. Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 2001;7:2168-81.
39. Crane CH, Thames HD, Hamilton SR. Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value? J Clin Oncol 2003;21:3381-2.
40. Tian H, Wittmack EK, Jorgensen TJ. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000;60:679-84.
41. St. Croix B, Florenes VA, Rak JW, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-10.
42. Achenbach TV, Muller R, Slater EP. Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1. Clin Cancer Res 2000;6:3006-14.
43. Naumann U, Weit S, Rieger L, Meyermann R, Weller M. p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. Biochem Biophys Res Commun 1999;261:890-6.
44. Motwani M, Jung C, Sirotnak FM, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001;7:4209-19.
45. Jung C, Motwani M, Kortmansky J, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res 2003;9:6052-61.
46. Gunther K, Jung A, Volker U, et al. p27(kip1) expression in rectal cancer correlates with disease-free survival. J Surg Res 2000;92:78-84.
47. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
48. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002;62:3950-5.